This episode of The Motley Fool's Market Checkup drills down on the day's hottest headlines and takes a look at two favorite health care-focused dividend stocks. Market Checkup gives a full examination of the recent regulatory action around a new blood cancer drug, a European orphan drug approval, and why a Big Pharma shockingly stopped the FDA from reviewing its newest diabetes drug.
In this video, health-care analysts David Williamson and Max Macaluso discuss Why Amgen's small but increasing dividend shouldn't be overlooked. Watch and find out about how Amgen's growth potential -- with its recent cancer-focused acquisition, next-gen cholesterol fighter, and biosimilar initiative -- combine with strong cash flow generation and a low payout ratio to form a dividend stock for the long term.
Get paid to invest
One of the best parts of owning Big Pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
Follow David on Twitter: @MotleyDavid.